Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$56.72 USD

56.72
1,625,021

+0.53 (0.94%)

Updated Oct 3, 2025 04:00 PM ET

After-Market: $56.60 -0.12 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Tirthankar Chakraborty headshot

New Strong Buy Stocks for July 19th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

    Tirthankar Chakraborty headshot

    New Strong Buy Stocks for July 17th

    by Tirthankar Chakraborty

    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

      Zacks Equity Research

      Why Exact Sciences (EXAS) Could Beat Earnings Estimates Again

      by Zacks Equity Research

      Exact Sciences (EXAS) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.

        Zacks Equity Research

        Exact Sciences (EXAS) Shows Strength: Stock Gains 11.7%

        by Zacks Equity Research

        Exact Sciences Corp. (EXAS) shares jumped almost 12% in the last trading session.

          Zacks Equity Research

          Pfizer's Leukemia Candidate Gets Priority Review in U.S.

          by Zacks Equity Research

          Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.

            Zacks Equity Research

            Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?

            by Zacks Equity Research

            Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.

              Zacks Equity Research

              Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?

              by Zacks Equity Research

              Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.

                Zacks Equity Research

                Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS

                by Zacks Equity Research

                Here we have three pharma companies that are set to report fourth-quarter results on Feb 21. Let's see how things are shaping up for this quarter.

                  Zacks Equity Research

                  Merrimack (MACK): What Awaits the Stock in Q4 Earnings?

                  by Zacks Equity Research

                  Merrimack Pharmaceuticals, Inc. (MACK) is scheduled to report fourth-quarter 2016 results in the next week. Last quarter, Merrimack delivered a positive earnings surprise of 23.33%.

                    Zacks Equity Research

                    Geron (GERN) Q4 Earnings: What's in Store for the Stock?

                    by Zacks Equity Research

                    Geron Corporation (GERN) is expected to report fourth-quarter 2016 results next week. In the last reported quarter, the company recorded a positive earnings surprise of 66.67%.

                      Zacks Equity Research

                      Can Fitbit (FIT) Stock Surprise Investors Post Q4 Earnings?

                      by Zacks Equity Research

                      Fitbit Inc. (FIT) is set to report fourth-quarter 2016 results on Feb 22. Last quarter, the company posted a positive earnings surprise of 18.18%.

                        Zacks Equity Research

                        BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?

                        by Zacks Equity Research

                        We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports fourth-quarter and full-year 2016 results on Feb 23

                          Zacks Equity Research

                          Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y

                          by Zacks Equity Research

                          Alexion Pharmaceuticals, Inc.'s (ALXN) fourth-quarter 2016 earnings (including stock-based compensation expense) of $1.10 cents per share compared with the year ago earnings of 78 cents.

                            Zacks Equity Research

                            Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat

                            by Zacks Equity Research

                            Alkermes plc (ALKS) reported loss of 4 cents per share (including the impact of share-based compensation expense) in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 19 cents.

                              Zacks Equity Research

                              Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?

                              by Zacks Equity Research

                              Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report fourth-quarter 2016 results on Feb 23, after the market closes.

                                Zacks Equity Research

                                What's in Store for ImmunoGen (IMGN) this Earnings Season?

                                by Zacks Equity Research

                                ImmunoGen, Inc. (IMGN) is scheduled to report results for the three months ended Dec 31, 2016 on Feb 17, before the opening bell. Overall, the company has posted an average negative surprise of 19.34%.

                                  Zacks Equity Research

                                  The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals

                                  by Zacks Equity Research

                                  The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals

                                    Swarup Gupta headshot

                                    5 Great Biotech Stocks to Buy Now

                                    by Swarup Gupta

                                    Biotechs have stabilized and still offer the potential to deliver substantial returns.

                                      Zacks Equity Research

                                      Cara Therapeutics (CARA) Worth Watching: Stock Jumps 8%

                                      by Zacks Equity Research

                                      Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares climb over 8% on the day.

                                        Zacks Equity Research

                                        Pfizer (PFE) C. Difficile Vaccine Positive in Phase II Study

                                        by Zacks Equity Research

                                        Pfizer Inc. (PFE) announced positive top-line results from a phase II study on its investigational vaccine candidate, PF-06425090, for the prevention of clostridium difficile infection.

                                          Zacks Equity Research

                                          Vertex Pharma's (VRTX) Q4 Earnings & Sales Beat; Stock Up

                                          by Zacks Equity Research

                                          Vertex Pharmaceuticals Inc. (VRTX) reported fourth-quarter 2016 earnings of 11 cents per share (including the impact of stock-based compensation expenses). The Zacks Consensus Estimate was of a loss of 1 cent per share.

                                            Tirthankar Chakraborty headshot

                                            New Strong Buy Stocks for January 26th

                                            by Tirthankar Chakraborty

                                            Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

                                              Tirthankar Chakraborty headshot

                                              New Strong Buy Stocks for December 29th

                                              by Tirthankar Chakraborty

                                              Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

                                                Kevin Matras headshot

                                                Get Ready To Be Surprised This Earnings Season

                                                by Kevin Matras

                                                Kevin Matras details a good screen to use before and after a company reports this earnings season. Highlighted stocks include ANIK, AMD, EW, EXAS and LTXB.